A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Recruiting · Phase 3 · NCT07011732
Conditions: Alzheimer Disease
At a glance
- Research payments reported, 2025
- $269,034
- U.S. investigators named
- 19
- Sites paid
- 18
- Planned or actual enrollment
- 426
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Xanomeline/Trospium Chloride Capsule (drug), Xanomeline Enteric Capsule (drug), Placebo (drug)
- Dates
- Started 2025-07-10; completion 2028-12-08
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $269,034 in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nida K. Laurin, M.D. Neurology · Scottsdale, AZ
- Sadiq L. Altamimi, MD Neurology · Pomona, CA
- Janne K. Nissinen, M.D. Neurology · La Jolla, CA
- Marina Raikhel, MD Family Medicine · Lomita, CA
- Jorge L. Jorge, MD Psychiatry · Miami, FL
- Brian Villa, M.D. Psychiatry · Miami, FL
- Alexander White, MD Family Medicine · Daytona Beach, FL
- Simon F. Desjardins SR., M.D. Psychiatry · New Bedford, MA
- Elia E. Acevedo Diaz, M.D Psychiatry · Gaithersburg, MD
- Jay H. Sandberg, D.O Internal Medicine · Troy, MI
- Eric J. Carbonell, M.D. Psychiatry · Festus, MO
- Awawu E. Igbinadolor, M.D. Adolescent Medicine · Monroe, NC
- Jelena Kunovac, M.D. Psychiatry · Las Vegas, NV
- Matthew G. Davis, MD Family Medicine · Rochester, NY
- Chet Villa, M.D. Pediatric Cardiology · Cincinnati, OH
- Sarah E. Land, D.O. Psychiatry · Tulsa, OK
- Eleanya Ogburu-ogbonnaya, M.D. Neurology · Columbia, SC
- Aamr A. Herekar, M.D. Neurology · El Paso, TX
- Albert O. Jarvi, M.D., M.A. Family Medicine · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Imaging Endpoints, Llc $62,664
- Mayflower Clinical $35,558
- Advanced Neurology Epilepsy and Sleep Center $33,537
- Redbird Research $31,205
- Progressive Medical Research $24,750
- Monroe Biomedical Research, Llc $22,215
- Central States Research, Llc $21,318
- Oakland Medical Research $17,673
- Torrance Clinical Research $3,758
- Kaizen Brain Center $3,250
- Cbh Health, Llc $2,467
- Patient First MD Advanced Center for Neurodiagnostics $2,008
- Hope Research Network $2,001
- Wellness Research Center $1,967
- The Neurology Group $1,271
- Wasatch Clinical Research $1,263
- Combined Research Orlando $1,205
- Midlands Neurology and PAin Associates, PA $925
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.